المؤلفون: Musacchio L, Caruso G, Pisano C, Cecere SC, Di Napoli M, Attademo L, Tambaro R, Russo D, Califano D, Palaia I, Muzii L, Benedetti Panici P, Pignata S

المصدر: Cancer Management and Research, Vol Volume 12, Pp 6123-6135 (2020)

مصطلحات موضوعية: endometrial cancer, parp inhibitors, pten mutation, p53 mutation, homologous recombination deficiency, immune checkpoint inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Lucia Musacchio,1 Giuseppe Caruso,1 Carmela Pisano,2 Sabrina Chiara Cecere,2 Marilena Di Napoli,2 Laura Attademo,2 Rosa Tambaro,2 Daniela Russo,3 Daniela Califano,3 Innocenza Palaia,1 Ludovico Muzii,1 Pierluigi Benedetti Panici,1 Sandro Pignata2 1Department of Maternal and Child Health and Urological Sciences, University “Sapienza”, Policlinico Umberto I, Rome, Italy; 2Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy; 3Functional Genomic Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, ItalyCorrespondence: Sandro PignataDepartment of Urology and Gynecology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Via Semmola, Naples 80131, ItalyTel +39 0815903409Fax +39 0815903861Email s.pignata@istitutotumori.na.itAbstract: Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors. This class of drugs that inhibit PARP enzymes has been investigated in many different types of tumors and its use in the treatment of gynecological malignancies has rapidly increased over the past few years. Data from several clinical trials showed that PARP inhibitors have a beneficial role in cancers with a defect in the homologous DNA recombination system, regardless of the BRCA mutational status. Since EC frequently shows mutations in PTEN and TP53 genes, indirectly involved in the homologous DNA recombination pathway, several in vivo and in vitro studies investigated the efficacy of PARP inhibitors in EC, showing promising results. This review will discuss the use of PARP inhibitors in endometrial cancer, summarizing data from preclinical studies and providing an overview of the ongoing trials, with a special focus on the development of combined treatment strategies with PARP inhibitors and immune checkpoint inhibitors.Keywords: endometrial cancer, PARP inhibitors, PTEN mutation, P53 mutation, homologous recombination deficiency, immune checkpoint inhibitors

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/parp-inhibitors-in-endometrial-cancer-current-status-and-perspectives-peer-reviewed-article-CMARTest; https://doaj.org/toc/1179-1322Test

الوصول الحر: https://doaj.org/article/62d78d8d1c834f8181e4ebcf48623914Test

المؤلفون: Musacchio L., Caruso G., Pisano C., Cecere S. C., Di Napoli M., Attademo L., Tambaro R., Russo D., Califano D., Palaia I., Muzii L., Panici P. B., Pignata S.

المساهمون: Musacchio, L., Caruso, G., Pisano, C., Cecere, S. C., Di Napoli, M., Attademo, L., Tambaro, R., Russo, D., Califano, D., Palaia, I., Muzii, L., Panici, P. B., Pignata, S.

مصطلحات موضوعية: endometrial cancer, homologous recombination deficiency, immune checkpoint inhibitor, P53 mutation, PARP inhibitor, PTEN mutation

الوصف: Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors. This class of drugs that inhibit PARP enzymes has been investigated in many different types of tumors and its use in the treatment of gynecological malignancies has rapidly increased over the past few years. Data from several clinical trials showed that PARP inhibitors have a beneficial role in cancers with a defect in the homologous DNA recombination system, regardless of the BRCA mutational status. Since EC frequently shows mutations in PTEN and TP53 genes, indirectly involved in the homologous DNA recombination pathway, several in vivo and in vitro studies investigated the efficacy of PARP inhibitors in EC, showing promising results. This review will discuss the use of PARP inhibitors in endome-trial cancer, summarizing data from preclinical studies and providing an overview of the ongoing trials, with a special focus on the development of combined treatment strategies with PARP inhibitors and immune checkpoint inhibitors.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32801862; info:eu-repo/semantics/altIdentifier/wos/WOS:000551486900001; volume:12; firstpage:6123; lastpage:6135; numberofpages:13; journal:CANCER MANAGEMENT AND RESEARCH; http://hdl.handle.net/11573/1481410Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85088242478

الإتاحة: https://doi.org/10.2147/CMAR.S221001Test
http://hdl.handle.net/11573/1481410Test

المؤلفون: Farolfi A., Scarpi E., Greco F., Bergamini A., Longo L., Pignata S., Casanova C., Cormio G., Bologna A., Orditura M., Zavallone L., Attademo L., Galla V., Franzese E., Pigozzi E., Loizzi V., Giorda G., Giardina D., Cioffi R., De Giorgi U.

المساهمون: Farolfi A., Scarpi E., Greco F., Bergamini A., Longo L., Pignata S., Casanova C., Cormio G., Bologna A., Orditura M., Zavallone L., Attademo L., Galla V., Franzese E., Pigozzi E., Loizzi V., Giorda G., Giardina D., Cioffi R., De Giorgi U.

مصطلحات موضوعية: ovarian cancer, platinum sensitivity, inflammatory indexes

الوصف: Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII) are prognostic factors in epithelial ovarian cancer (EOC). Their predictive value for platinum-sensitivity and their role in recurrent EOC are unknown. A total of 375 EOC patients were retrospectively analyzed. The correlation between baseline NLR and SII, and platinum-free interval (PFI) according to first line bevacizumab treatment were analyzed using logistic regression analyses adjusted for baseline patient characteristics. Subsequently NLR and SII calculated before second line treatment initiation were evaluated to identify a potential correlation with progression-free survival (PFS) and overall survival (OS) in platinum-sensitive and in platinum-resistant population. In multivariate analysis, NLR ≥ 3 is an independent predictive factor for PFI at 6months in the chemotherapy group (OR = 2.77, 95% CI 1.38–5.56, p = 0.004), not in bevacizumab treated patients. After having adjusted for ECOG performance status, histology, ascites, bevacizumab treatment at second line and BRCA status, NLR ≥ 3 and SII ≥ 730 are significantly associated with worse OS in platinum-sensitive (HR = 2.69, 95% CI 1.60–4.53, p = 0.002; HR = 2.11, 95% CI 1.29–3.43, p = 0.003, respectively), not in platinum-resistant EOC patients. Low NLR is an independentpredictive factorfor platinum-sensitivity in patients treated without bevacizumab. NLR and SII are prognostic factors in recurrent platinum-sensitive EOC patients.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33097745; info:eu-repo/semantics/altIdentifier/wos/WOS:000586493900005; volume:10; issue:1; firstpage:1; lastpage:8; numberofpages:8; journal:SCIENTIFIC REPORTS; https://hdl.handle.net/11585/966469Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093980591; https://www.nature.com/articles/s41598-020-75316-xTest

الإتاحة: https://doi.org/10.1038/s41598-020-75316-xTest
https://hdl.handle.net/11585/966469Test
https://www.nature.com/articles/s41598-020-75316-xTest

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Bernardini F., Attademo L., Trezzi R., Gobbicchi C., Balducci P. M., Del Bello V., Menculini G., Pauselli L., Piselli M., Sciarma T., Moretti P., Tamantini A., Quartesan R., Compton M. T., Tortorella A.

المساهمون: Bernardini, F., Attademo, L., Trezzi, R., Gobbicchi, C., Balducci, P. M., Del Bello, V., Menculini, G., Pauselli, L., Piselli, M., Sciarma, T., Moretti, P., Tamantini, A., Quartesan, R., Compton, M. T., Tortorella, A.

مصطلحات موضوعية: Air pollution, emergency service, environmental pollutant, hospital, mental health

الوصف: AIMS: Aim of the current study is to investigate the associations between daily levels of air pollutants (particulate matter, ozone, carbon monoxide, nitrogen dioxide) and daily admissions for mental disorders to the emergency department of two general hospitals in Umbria region (Italy). METHODS: We collected data about daily admissions to psychiatric emergency services of two general hospitals, air pollutants' levels and meteorological data for the time period 1 January 2015 until 31 December 2016. We assessed the impact of an increase in air pollutants on the number of daily admissions using a time-series econometric framework. RESULTS: A total of 1860 emergency department admissions for mental disorders were identified. We observed a statistically significant impact of ozone levels on daily admissions. The estimated coefficient of O3 is statistically significant at the 1% level. All other pollutants were not significantly associated with the number of daily admissions. CONCLUSIONS: Short-term exposure to ozone may be associated with increased psychiatric emergency services admissions. Findings add to previous literature on existing evidence for air pollution to have an impact on mental health. Ozone may be considered a potential environmental risk factor for impaired mental health.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31690359; info:eu-repo/semantics/altIdentifier/wos/WOS:000585066900041; volume:29; firstpage:e66; journal:EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES; http://hdl.handle.net/11391/1459799Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076385787; https://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/air-pollutants-and-daily-number-of-admissions-to-psychiatric-emergency-services-evidence-for-detrimental-mental-health-effects-of-ozone/581CC5CBFC954B0A78115B025C0CE103Test

الإتاحة: https://doi.org/10.1017/S2045796019000623Test
http://hdl.handle.net/11391/1459799Test
https://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/air-pollutants-and-daily-number-of-admissions-to-psychiatric-emergency-services-evidence-for-detrimental-mental-health-effects-of-ozone/581CC5CBFC954B0A78115B025C0CE103Test

المؤلفون: De Giorgi U., Casadei C., Bergamini A., Attademo L., Cormio G., Lorusso D., Pignata S., Mangili G.

المساهمون: De Giorgi, U., Casadei, C., Bergamini, A., Attademo, L., Cormio, G., Lorusso, D., Pignata, S., Mangili, G.

مصطلحات موضوعية: Female patient, Germ cell tumor, High-dose chemotherapy, Ovarian germ cell tumor, Refractory, Salvage therapy

الوصف: The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. The treatment of cisplatin-resistant disease is challenging and prognosis remains poor. There are limited data on the efficacy of specific chemotherapeutic regimens, high-dose chemotherapy with autologous progenitor cell support and targeted therapies. The inclusion of patients in clinical trials is strongly recommended, especially in clinical trials on the most frequent male germ cell tumors, to offer wider therapeutic opportunities. Here, we provide an overview of current and potential new treatment options including combination chemotherapy, high-dose chemotherapy and molecular targeted therapies, for patients with cisplatin-resistant ovarian germ cell tumors.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31627378; info:eu-repo/semantics/altIdentifier/wos/WOS:000498826000181; volume:11; issue:10; firstpage:1584; journal:CANCERS; http://hdl.handle.net/11586/359905Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85074948787

الإتاحة: https://doi.org/10.3390/cancers11101584Test
http://hdl.handle.net/11586/359905Test

المؤلفون: Tortorella, A, Menculini, G, Moretti, P, Attademo, L, Balducci, PM, Bernardini, F, Cirimbilli, F, Chieppa, AG, Ghiandai, N, Erfurth, A

المساهمون: Tortorella, A, Menculini, G, Moretti, P, Attademo, L, Balducci, Pm, Bernardini, F, Cirimbilli, F, Chieppa, Ag, Ghiandai, N, Erfurth, A

مصطلحات موضوعية: noise pollution, urban environment, mental health, psychopathology, psychiatric symptoms

الوصف: Urbanisation processes and anthropogenic actions led to a significant increase in pollution levels, with relevant consequences on global health. In particular, noise pollution demonstrated an association with cardiovascular, metabolic, and respiratory diseases. Furthermore, increasing evidence underlined the possible role of air and noise pollution in the development of psychiatric disorders. In this narrative review, evidence concerning the relationship between noise pollution and the emergence of psychiatric symptoms or psychiatric disorders is summarised. After the literature search process was completed, 40 papers were included in the present review. The exposure to road-, rail-, and air- traffic represented a risk factor for the emergence of affective disorders. This could also be mediated by the occurrence of circadian rhythms disturbances or by noise annoyance and noise sensitivity, both influencing psychological well-being and health-related quality of life. Fewer studies concentrated on special populations, particularly pregnant women and children, for whom noise pollution was confirmed as a risk factor for psychopathology. The better clarification of the complex interaction between noise pollution and mental health may help to identify subjects at risk and targeting specific prevention and intervention strategies in the urban environment.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000826019800001; volume:34; issue:7-8; firstpage:783; lastpage:796; numberofpages:14; journal:INTERNATIONAL REVIEW OF PSYCHIATRY; https://hdl.handle.net/11391/1540916Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85134191237

الإتاحة: https://doi.org/10.1080/09540261.2022.2095200Test
https://hdl.handle.net/11391/1540916Test

المؤلفون: Bernardini F., Attademo L., Trezzi R., Gobbicchi C., Balducci P., Del Bello ., Menculini G., Pauselli L., Piselli M., Sciarma T., Moretti P., Tamantini A., Quartesan R., Compton M., Tortorella A.

المساهمون: Bernardini F., Attademo L., Trezzi R., Gobbicchi C., Balducci P., Del Bello ., Menculini G., Pauselli L., Piselli M., Sciarma T., Moretti P., Tamantini A., Quartesan R., Compton M., Tortorella A., Bernardini, F., Attademo, L., Trezzi, R., Gobbicchi, C., Balducci, P., Del Bello, ., Menculini, G., Pauselli, L., Piselli, M., Sciarma, T., Moretti, P., Tamantini, A., Quartesan, R., Compton, M., Tortorella, A.

مصطلحات موضوعية: Air pollutants, Psychiatric services, Environmental health, Psychiatric disorders

الوصف: Psychiatric services

وصف الملف: STAMPA

العلاقة: ispartofbook:Supplement 1; Congress of the Schizophrenia-International-Research-Society (SRIS); firstpage:277; lastpage:278; numberofpages:2; journal:SCHIZOPHRENIA BULLETIN; http://hdl.handle.net/11391/1478423Test

الإتاحة: http://hdl.handle.net/11391/1478423Test

المؤلفون: Rosanova, M., De Falco, S., Attademo, L., Fiore, G., De Stefano, A., Maddalena, C., De Placido, S., Carlomagno, C.

المصدر: Annals of Oncology ; volume 28, page vi8-vi9 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdx422.018Test
https://api.elsevier.com/content/article/PII:S0923753420346895?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420346895?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/28/suppl_6/mdx422.018/21490371/mdx422.018.pdfTest

المؤلفون: Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G

المساهمون: Santini, D, Stellato, M, De Giorgi, U, Pantano, F, De Lisi, D, Casadei, C, Maruzzo, M, Bimbatti, D, Naglieri, E, Buti, S, Bersanelli, M, De Vivo, R, Di Lorenzo, G, Sbrana, A, Verzoni, E, Soraru', M, Fornarini, G, Mucciarini, C, Grillone, F, Mini, E, Vignani, F, Attademo, L, Pignata, S, Procopio, G

مصطلحات موضوعية: cabozantinib, immune-oncology, immunotherapy, renal cell carcinoma, therapeutic sequence, Aged, Anilide, Antineoplastic Combined Chemotherapy Protocol, Carcinoma, Renal Cell, Disease Progression, Everolimu, Female, Human, Immune Checkpoint Inhibitor, Italy, Kidney Neoplasm, Male, Middle Aged, Nivolumab, Programmed Cell Death 1 Receptor, Pyridine, Retrospective Studie, Treatment Outcome

الوصف: Objectives:The aim of our study was to collect data about of the outcome of metastatic renal cell carcinoma patients who progressed after immune checkpoint inhibitors in order to enhance data about efficacy and safety of treatment beyond immune-oncology (IO).Materials and Methods:A total of 162 eligible patients, progressing to IO, were enrolled from 16 Italian referral centers adhering to the Meet-Uro association. Baseline characteristics, outcome data and toxicities were retrospectively collected. Descriptive analysis was made using median values and ranges. Kaplan-Meier method and Mantel-Haenszel log-rank test were performed to compare differences between groups.Results:A total of 111 patients (68.5%) were treated after IO progression. In all, 51 patients (31.5%) did not receive further treatment for clinical deterioration. Median IO progression free survival (PFS) was 4 months (95% confidence interval [CI]: 3.1-4.8). IO-PFS tends to be longer in patients reporting adverse events (AE) of any grade (5.03 [95% CI: 3.8-6.1] vs. 2.99 [95% CI: 2.4-3.5] months P=0.004). Subsequent therapies included cabozantinib (n=79, 48%), everolimus (n=11, 6.7%), and others (n=21, 12.9%).Median PFS post-IO was 6.5 months (95% CI: 5.1-7.8). Cabozantinib showed longer PFS compared with everolimus (7.6 mo [95% CI: 5.2-10.1] vs. 3.2 mo [95% CI: 1.8-4.5]) (hazard ratio: 0.2; 95% CI: 0.1026-0.7968) and other drugs (4.3 mo [95% CI: 1.3-7.4]) (hazard ratio: 0.6; 95% CI: 0.35-1.23). All grade AE were reported in 83 patients (74%) and G3 to G4 AE in 39 patients (35%). Target therapies post-IO showed median overall survival of 14.7 months (95% CI: 0.3-21.4).Conclusions:In our real world experience after progression to IO, vascular endotelial groth factor-tyrosine kinase inhibitors, given to patients, proved to be active and safe choices. Cabozantinib was associated with a better outcome in terms of median PFS.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33617179; info:eu-repo/semantics/altIdentifier/wos/WOS:000622345800006; volume:44; issue:3; firstpage:121; lastpage:125; numberofpages:5; journal:AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS; https://hdl.handle.net/11573/1641932Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85101735961

الإتاحة: https://doi.org/10.1097/COC.0000000000000791Test
https://hdl.handle.net/11573/1641932Test